Main Article Content
Upper tract urothelial carcinoma, transitional cell carcinoma, nephroureterectomy, ureteroscopy, management pathway
Background and Objective
Upper tract urothelial carcinoma (UTUC) is rare in comparison to urothelial carcinoma of the bladder or renal cell carcinoma. UTUC may present with loin pain, haematuria or alternatively can be identified as an incidental finding on imaging. There are often delays to diagnosis as haematuria clinics are efficient for bladder and renal cancer but less effective for UTUC. The diagnosis and treatment of UTUC is more challenging, as it often requires two operations and multiple MDT discussions. Diagnosis must be certain to avoid unnecessary radical surgery.
We found that our patients were experiencing significant delays to definitive surgery. Our patients currently follow the pathway for bladder and renal cancer, as there is no UTUC pathway at or trust or published in the literature. We audited our diagnostic pathway to see how we could tailor the pathway to be more effective for patients with UTUC. This will ensure that more patients will meet the NHS 62-day targets.
Materials and Methods
A retrospective review of patients management pathway from December 2008 to December 2018. Patients were identified by the pathological code for UTUC.
A total of 62 patients underwent nephroureterectomy during a 10-year period. 48 patients were analysed. The median waiting time for haematuria clinic from referral was 21days, a further 73 days to ureterorenoscopy and biopsy, and then 14 days to definitive nephroureterectomy. Only one patient met the NHS 62-day treatment target.
Our waiting times are comparable with other published international series. We have implemented a new UTUC pathway to streamline the diagnosis and management of UTUC. Some patients with UTUC will still have inevitable delays as diagnosis can be very challenging but this new pathway should improve the patient journey and reduce the waiting times significantly.
2.Cosentino M, Palou J, Gaya JM et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World journal of urology. 2013 Feb 1;31(1):141-5.
3.Connolly SS, Rochester MA, Baus. Nephroureterectomy surgery in the UK in 2012: British Association of Urological Surgeons (BAUS) Registry data. BJU international. 2015 Nov;116(5):780-90.
4.Margulis V, Shariat SF, Matin SF et al. Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009 Mar 15;115(6):1224-33.
5.Compérat E, Larré S, Roupret M et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Archiv. 2015 May 1;466(5):589-94.
6.Edwards TJ, Dickinson AJ, Natale S et al. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol‐driven haematuria clinic. BJU international. 2006 Feb;97(2):301-5.
7.Cauberg EC, Nio CY, de la Rosette JM et al. Computed tomography-urography for upper urinary tract imaging: is it required for all patients who present with hematuria?. Journal of endourology. 2011 Nov 1;25(11):1733-40.
8.Viswanath S, Zelhof B, Ho E et al. Is routine urine cytology useful in the haematuria clinic?. The Annals of The Royal College of Surgeons of England. 2008 Mar;90(2):153-5.
9.Potretzke AM, Knight BA, Potretzke TA, Larson JA, Bhayani SB. Is ureteroscopy needed prior to nephroureterectomy? An evidence-based algorithmic approach. Urology. 2016 Feb 1;88:43-8.
10. Williams SK, Denton KJ, Minervini A, Oxley J, Khastigir J, Timoney AG, Keeley FX. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. Journal of endourology. 2008 Jan 1;22(1):71-6.
11. Al-Qahtani SM, Legraverend D, Traxer O et al. Can we improve the biopsy quality of upper urinary tract urothelial tumors? Single-center preliminary results of a new biopsy forceps. Urologia internationalis. 2014;93(1):34-7.
12. Guarnizo E, Pavlovich CP, Seiba M et al. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. The Journal of urology. 2000 Jan 1;163(1):52-5.
13. Vashistha V, Shabsigh A, Zynger DL. Utility and diagnostic accuracy of ureteroscopic biopsy in upper tract urothelial carcinoma. Archives of pathology & laboratory medicine. 2013 Mar;137(3):400-7.
14. Nison L, Rouprêt M, Bozzini G, Ouzzane A, Audenet F, Pignot G, Ruffion A, Cornu JN, Hurel S, Valeri A, Roumiguie M. The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database. World journal of urology. 2013 Feb 1;31(1):69-76.
15. Sundi D, Svatek RS, Margulis V et al. Upper tract urothelial carcinoma: impact of time to surgery. InUrologic Oncology: Seminars and Original Investigations 2012 May 1 (Vol. 30, No. 3, pp. 266-272). Elsevier.
16. Shiraishi K, Eguchi S, Mohri J, Kamiryo Y. Role of ureteroscopic biopsy in the management of upper urinary tract malignancy. International journal of urology. 2003 Dec;10(12):627-30.
17. Boorjian S, Ng C, Munver R et al. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology. 2005 Aug 1;66(2):283-7.
18. Gadzinski AJ, Roberts WW, Faerber GJ et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. Journal of endourology. 2012 May 1;26(5):566-73.
19. Hong S, Kwon T, You D et al. Incidence of benign results after laparoscopic radical nephroureterectomy. JSLS: Journal of the Society of Laparoendoscopic Surgeons. 2014 Oct;(4).